Cancer Research UK begins Phase I of Lilly's CDC7 inihibitor in solid tumors

Cancer Research UK (London, U.K.) began a Phase I trial of LY3143921 to treat advanced solid tumors, including bowel, lung, ovarian, urothelial, pancreatic, breast, head and neck, and esophageal tumors in about 68 patients. The study will evaluate once-daily oral LY3143921 in 21-day cycles for up to 12 cycles. The 2-part, open-label, dose-escalation, U.K. trial's primary endpoint is maximum tolerated dose (MTD). Secondary endpoints include pharmacokinetics and progression-free survival (PFS)...